EFTI at 90, page-3

Eftilagimod is the first in its class treatment.
Choosing the lowest effective dose was the only choice
A higher dose could have resulted in side effects which would have sank the whole enterprise

Now that we are seeing better results with 90 mg and efficacy in difficult to treat soft tissue sarcomas we should see a number of new studies. IMM needs maximum exposure when announcing new studies

If I was in charge I would arranging deals and would not say anything until ASCO. Then I would release a number of new studies and make eftilagimod will be the topic of conversation at this year’s meeting. Maybe the matra will be “anyone who is studying cancer treatment without eftilagimod isn’t serious about curing it”